A citation-based method for searching scientific literature

M A Nauck, S Del Prato, S Durán-García, K Rohwedder, A M Langkilde, J Sugg, S J Parikh. Diabetes Obes Metab 2014
Times Cited: 80

List of shared articles

Times cited

Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
Abd A Tahrani, Anthony H Barnett, Clifford J Bailey. Nat Rev Endocrinol 2016

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.
Maria J Pereira, Jan W Eriksson. Drugs 2019

Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
Konstantinos P Imprialos, Pantelis A Sarafidis, Asterios I Karagiannis. J Hypertens 2015

The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Konstantinos P Imprialos, Konstantinos Stavropoulos, Michael Doumas, Asterios Karagiannis, Vasilios G Athyros. Expert Rev Clin Pharmacol 2017

Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
S Del Prato, M Nauck, S Durán-Garcia, L Maffei, K Rohwedder, A Theuerkauf, S Parikh. Diabetes Obes Metab 2015

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll. PLoS One 2016

Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure.
Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios Papademetriou. Heart Fail Clin 2019

The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis, Pantelis Sarafidis. Future Med Chem 2019

New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.
Belén Dalama, Jordi Mesa. Rev Esp Cardiol (Engl Ed) 2016